Skip to main content
SpringerLink
Log in

Impact of the whole activated clotting time during Impella support on short-term prognosis

  • Original Article
  • Artificial Heart (Clinical)
  • Published:
Journal of Artificial Organs Aims and scope Submit manuscript

Abstract

Impella (Abiomed, Danvers, MA, USA) is a percutaneous trans-catheter left ventricular assist device. Anticoagulant therapy targeting whole activated clotting time (ACT) between 160 and 180 s is recommended to prevent pump thrombosis during support. However, we sometimes experience fatal bleeding despite achieving the target ACT range. Consecutive patients who received Impella support in our institute between March 2018 and October 2020 were included in this retrospective study. The association between the averaged ACT levels during the Impella support and 30-day mortality was investigated. A total of 36 patients (71 years old, 61% males) were included. Most of the patients were managed within the recommended therapeutic range of ACT, and the average ACT level was 162 s. The higher ACT group (> 168 s) had older age, smaller body mass index, and higher serum creatinine compared with the lower ACT group (p < 0.05 for all). A higher ACT level was an independent risk factor of 30-day mortality with an adjusted hazard ratio of 1.085 (95% confidence interval 1.037–1.154) with a cut-off level of 168 s. There were only two thromboembolic events. Patients managed with higher ACT levels had a higher risk of 30-day mortality during Impella support. A low-dose heparin purge solution might be recommended in patients with high-risk for bleeding events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2:

Similar content being viewed by others

References

  1. Burkhoff D, Sayer G, Doshi D, Uriel N. Hemodynamics of mechanical circulatory support. J Am Coll Cardiol. 2015;66:2663–74.

    Article  Google Scholar 

  2. Basir MB, Kapur NK, Patel K, et al. National cardiogenic shock initiative i. improved outcomes associated with the use of shock protocols: updates from the national cardiogenic shock initiative. Catheter Cardiovasc Interv. 2019;93:1173–83.

    PubMed  Google Scholar 

  3. Patel N, Sharma A, Dalia T, et al. Vascular complications associated with percutaneous left ventricular assist device placement: a 10-year US perspective. Catheter Cardiovas Interv. 2020;95:309–16.

    Article  Google Scholar 

  4. Badiye AP, Hernandez GA, Novoa I, Chaparro SV. Incidence of hemolysis in patients with cardiogenic shock treated with Impella percutaneous left ventricular assist device. ASAIO J. 2016;62:11–4.

    Article  CAS  Google Scholar 

  5. Esposito ML, Morine KJ, Annamalai SK, et al. Increased plasma-free hemoglobin levels identify hemolysis in patients with cardiogenic shock and a trans valvular micro-axial flow pump. Artif Organs. 2019;43:125–31.

    Article  CAS  Google Scholar 

  6. Davis ME, Haglund NA, Tricarico NM, et al. Development of acquired von Willebrand syndrome during short-term micro axial pump support: implications for bleeding in a patient bridged to a long-term continuous-flow left ventricular assist device. ASAIO J. 2014;60:355–7.

    Article  CAS  Google Scholar 

  7. Goldfarb M, Czer LS, Lam LD, et al. High molecular weight von willebrand factor multimer loss and bleeding in patients with short-term mechanical circulatory support devices: a case series. J Extra Corpor Technol. 2018;50:77–82.

    PubMed  PubMed Central  Google Scholar 

  8. Dietrich JN, Kazmi H. Bleeding risks in patients on percutaneous ventricular assist devices receiving two different dextrose concentrations of heparinized purge solution: a case series. J Pharm Pract. 2019;32:464–9.

    Article  Google Scholar 

  9. Schrage B, Ibrahim K, Loehn T, et al. Impella support for acute myocardial infarction complicated by cardiogenic shock. Circulation. 2019;139:1249–58.

    Article  Google Scholar 

  10. Wernly B, Seelmaier C, Leistner D, et al. Mechanical circulatory support with Impella versus intra-aortic balloon pump or medical treatment in cardiogenic shock-a critical appraisal of current data. Clin Res Cardiol. 2019;108:1249–57.

    Article  CAS  Google Scholar 

  11. Succar L, Sulaica EM, Donahue KR, Wanat MA. Management of anticoagulation with Impella® percutaneous ventricular assist devices and review of new literature. J Thromb Thrombolysis. 2019;48:284–91.

    Article  CAS  Google Scholar 

  12. Flierl U, Tongers J, Berliner D, et al. Acquired von Willebrand syndrome in cardiogenic shock patients on mechanical circulatory microaxial pump support. PLoS ONE. 2017;12:e0183193.

    Article  Google Scholar 

  13. Reed BN, DiDomenico RJ, Allender JE, et al. Survey of anticoagulation practices with the Impella percutaneous ventricular assist device at high-volume centers. J Interv Cardiol. 2019;2019:3791307.

    Article  Google Scholar 

  14. Copotoiu R, Cinca E, Collange O, et al. Pathophysiology of hemorragic shock. Transfusion clinique et biologique: Transfus Clin Biol. 2016;23:222–8.

    Article  CAS  Google Scholar 

  15. Smythe MA, Koerber JM, Nowak SN, et al. Correlation between activated clotting time and activated partial thromboplastin times. Ann Pharmacother. 2002;36:7–11.

    Article  CAS  Google Scholar 

  16. Schurr JW, Muske AM, Stevens CA, et al. Derivation and validation of age- and body mass index-adjusted weight-based unfractionated heparin dosing. Clin Appl Thromb Hemost. 2019;25:1076029619833480.

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Second Department of Internal Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930-0194, Japan

    Makiko Nakamura, Teruhiko Imamura, Hiroshi Ueno, Masakazu Hori, Ryuichi Ushijima & Koichiro Kinugawa

Authors
  1. Makiko Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Teruhiko Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroshi Ueno
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masakazu Hori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryuichi Ushijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Koichiro Kinugawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Teruhiko Imamura.

Ethics declarations

Conflict of interest

There is no conflict of interest related to this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, M., Imamura, T., Ueno, H. et al. Impact of the whole activated clotting time during Impella support on short-term prognosis. J Artif Organs 25, 9–15 (2022). https://doi.org/10.1007/s10047-021-01271-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10047-021-01271-7

Keywords

Search

Navigation